Category Archives: The IPO Buzz

Acrivon Therapeutics (ACRV) priced its IPO at $12.50 – far below its initial price range of $16.00 to $18.00 – and sold 7.55 million shares (7,550,000 shares) on Monday night (Nov. 14, 2022) to raise $94.38 million. That’s a much smaller deal than the cancer biotech had originally planned. Acrivon Therapeutics initially expected to raise […]

Atour Lifestyle Holdings Ltd. (ATAT), a leading midscale hotel chain in China, flew first class in its NASDAQ debut on Friday (Nov. 11, 2022). Atour’s stock soared 41 percent to open at $15.50 – up $4.50 from its $11.00 IPO price – in its opening trade at 10:33 a.m. EST on Friday, NASDAQ records showed, […]

Acrivon Therapeutics (ACRV proposed), a cancer biotech aiming to raise $100.3 million, leads a life sciences-focused IPO Calendar of seven deals during this election week. This is the first big IPO ($100 million-plus) to land on the IPO Calendar since Mobileye Global, Inc. (MBLY) scored its successful IPO in late October. Four of this week’s seven deals are from […]

Acrivon Therapeutics (ACRV proposed), a cancer biotech, filed terms – 5.9 million shares at $16.00 to $18.00 – early today (Thursday, Nov. 3, 2022) and landed on next week’s IPO Calendar. The deal, which will raise $100.3 million if priced at the $17.00 mid-point, launched today as well. It’s set to price on Wednesday night, […]

After Mobileye (MBLY), what’s next? So far, only three tiny deals – two IPOs and a NASDAQ uplisting – are on the IPO Calendar this week. With Halloween falling on Monday this year, maybe IPO bankers had the right idea to not schedule any deals for pricing after the close. (Editor’s Note: This column, published on […]

Mobileye Global, Inc. (MBLY) raced onto the IPO freeway – running up 37.95 percent to close at $28.97 today – its first day of NASDAQ trading. Volume: 27,929,867 shares. The stock roared out of the gate – rising 27.2 percent to $26.71 in its opening trade today (Oct. 26, 2022) on the NASDAQ on volume of […]

Mobileye Global (MBLY proposed), Intel’s self-driving car unit, is ready to cruise onto the IPO freeway this week with its $779 million deal – one of the most highly anticipated IPOs of the year. Mobileye’s IPO – 41.0 million shares at $18.00 to $20.00 – is set for pricing Tuesday night (Oct. 25, 2022) to trade […]

Talk about a healthy start.  Prime Medicine, Inc. (PRME) started NASDAQ trading shortly after noon EDT today at $18.97 – up $1.97 or 11.6 percent from its $17.00 IPO price. The first trade occurred at 12:11 p.m. EDT on volume of 532,337 shares, NASDAQ records show. By early afternoon, though, the stock gave up its early […]

Mobileye Global (MBLY proposed), Intel’s self-driving car unit, stepped on the gas early today – filing terms for its highly anticipated IPO – to give the Israeli company a valuation of about $15.13 billion. That’s a hair less than what Intel paid for Mobileye in 2017. Mobileye’s S-1/A filing popped through the SEC’s filing window […]

Momentum may be the word of the day. Prime Medicine, Inc. (PRME proposed) – a pre-clinical gene editing company – plans to raise $151.3 million this week. Mobileye Global (MBLY proposed), Intel’s self-driving car unit, may be up next. The Wall Street Journal reported late Monday (Oct. 17, 2022) that Mobileye is likely to cut […]